Shijiazhuang Fourth Pharmaceutical Group (02005) has bid for a total of thirteen varieties and sixteen specifications of products, all of which are intended to be selected for national centralized drug procurement.

Zhitong Finance APP reported that Shisi Pharmaceutical Group (02005) announced that in the recent 12th national centralized procurement tender for medicines in China, the Group's bids for a total of thirteen varieties and sixteen specifications of products are all planned to be selected. These include: Bunanserin Tablets (4mg), Mesylate Betahistine Tablets (6mg), Vitamin B6 Injection (1ml:0.1g), Aximorcis Capsules (0.25g), Mesylate Doxazosin Sustained-Release Tablets (4mg), Bisoprolol and Amlodipine Tablets (containing Bisoprolol Fumarate 5mg and Amlodipine Besylate 5mg), Perindopril and Amlodipine Tablets (III) (containing Arginine Perindopril 10mg and Amlodipine Besylate 5mg), Nicardipine Hydrochloride Injection (10ml:10mg) and Nicardipine Hydrochloride Sodium Injection (200ml: Nicardipine Hydrochloride 20mg and Sodium Chloride 1.72g), Bumetanide Injection (2ml:1mg and 1ml:0.5mg), Ketoconazole Sustained-Release Tablets (0.4g), Delarolax Dispersible Tablets (125mg), Compound Potassium Dihydrogen Phosphate Injection (5ml: Potassium Dihydrogen Phosphate 1.12g and Dipotassium Hydrogen Phosphate 1.18g and 2ml: Potassium Dihydrogen Phosphate 0.448g and Dipotassium Hydrogen Phosphate 0.472g), and Calcium Chloride Injection (10ml:1g).